Mehrdad Zarei

Mehrdad Zarei

Auto-generated profile, based on publicly available information

Mehrdad Zarei

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAli Vaziri-Gohar
Ali Vaziri-Gohar
JHJonathan J. Hue
Jonathan J. Hue
AAAta Abbas
Ata Abbas
HGHallie J. Graor
Hallie J. Graor
OHOmid Hajihassani
Omid Hajihassani
JWJordan M. Winter
Jordan M. Winter
Pancreatic Ductal Adenocarcinoma (PDAC) is highly resistant to chemotherapy. Effective alternative therapies have yet to emerge, as chemotherapy remains the best available systemic treatment. However, the discovery of safe and available adjuncts to enhance chemotherapeutic efficacy can still improve survival outcomes. We show that a hyperglycemic state substantially enhances the efficacy of conventional single- and multi-agent chemotherapy regimens against PDAC. Molecular analyses of tumors exposed to high glucose levels reveal that the expression of GCLC (glutamate-cysteine ligase catalytic subunit), a key component of glutathione biosynthesis, is diminished, which in turn augments oxidative anti-tumor damage by chemotherapy. Inhibition of GCLC phenocopies the suppressive effect of forced hyperglycemia in mouse models of PDAC, while rescuing this pathway mitigates anti-tumor effects observed with chemotherapy and high glucose.

1 December 2025 in Non-coding RNA Research
Verified
Journal Article
Open access
EKErryk S. Katayama
Erryk S. Katayama
JHJonathan J. Hue
Jonathan J. Hue
ALAlexander W. Loftus
Alexander W. Loftus
SASemmer A. Ali
Semmer A. Ali
HGHallie J. Graor
Hallie J. Graor
JWJordan M. Winter
Jordan M. Winter
To verify the stability and reliability of circulating microRNA (miRNA) profiles in plasma and serum under different processing and storage conditions to inform future applications to circulating biomarker analyses. The development of blood-based methods for early disease detection has become increasingly desirable across various medical fields. RNA profiles have been investigated but have been a challenge due to rapid degradation of the analyte by ubiquitous RNases. miRNAs are short, non-coding regulatory RNAs that are believed to be more stable under certain conditions, large in number, and specific to cell type and disease state. Thus, circulating miRNA profiles hold significant promise as diagnostic biomarkers for a range of conditions, including cancer, autoimmune, liver, neurological, metabolic, and cardiovascular diseases. However, to realize their full potential in clinical applications, it is crucial to thoroughly characterize the stability of miRNAs under various blood collection, processing, and storage conditions prior to their investigation and large-scale application in disease-specific biomarker discovery studies. Plasma or serum were extracted from whole blood of healthy volunteers. Samples were stored at different temperatures (4 °C or 25 °C, room temperature) for varying periods (0–24 h) to mimic possible delays in processing encountered in routine clinical settings. miRNA was extracted and profiles were assessed with RT-qPCR or small RNA-sequencing techniques. Mean Cq values of specific miRNAs, such as miR-15b, miR-16, miR-21, miR-24, and miR-223, remained consistent between 0 and 24 h when serum and plasma were stored on ice. Minimal changes were observed in mean Cq values over 24 h when serum was left at room temperature as well. Similar trends were observed when miRNAs from plasma were analyzed. Small-RNA sequencing detected approximately ∼650 different miRNA signals in plasma, with over 99 % of the miRNA profile unchanged even when blood draw tubes were left at room temperature for 6 h prior to processing. These data demonstrate remarkable stability of miRNAs over time, which should withstand variability in handling and processing that can occur with routine clinical lab draws. Considering the large diversity of miRNAs, this analyte class should be thoroughly investigated as a non-invasive biomarker of diverse disease states.

6 June 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
MZMehrdad Zarei
Mehrdad Zarei
OHOmid Hajihassani
Omid Hajihassani
JHJonathan J. Hue
Jonathan J. Hue
ALAlexander W. Loftus
Alexander W. Loftus
HGHallie J. Graor
Hallie J. Graor
JWJordan M. Winter
Jordan M. Winter
Pancreatic ductal adenocarcinoma (PDAC) is associated with a 5-year overall survival rate of just 13%, and development of chemotherapy resistance is nearly universal. PDAC cells overexpress wild-type isocitrate dehydrogenase 1 (IDH1) that can enable them to overcome metabolic stress, suggesting it could represent a therapeutic target in PDAC. Here, we found that anti-IDH1 therapy enhanced the efficacy of conventional chemotherapeutics. Chemotherapy treatment induced reactive oxygen species (ROS) and increased tricarboxylic acid cycle activity in PDAC cells, along with the induction of wild-type IDH1 expression as a key resistance factor. IDH1 facilitated PDAC survival following chemotherapy treatment by supporting mitochondrial function and antioxidant defense to neutralize ROS through the generation of α-ketoglutarate and NADPH, respectively. Pharmacologic inhibition of wild-type IDH1 with ivosidenib synergized with conventional chemotherapeutics in vitro and potentiated the efficacy of subtherapeutic doses of these drugs in vivo in murine PDAC models. This promising treatment approach is translatable through available and safe oral inhibitors and provides the basis of an open and accruing clinical trial testing this combination (NCT05209074). Significance: Targeting IDH1 improves sensitivity to chemotherapy by suppressing mitochondrial function and inducing oxidative stress, supporting the potential of the combination as an effective strategy for treating pancreatic cancer.

3 October 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
JHJonathan J. Hue
Jonathan J. Hue
HGHallie J. Graor
Hallie J. Graor
MZMehrdad Zarei
Mehrdad Zarei
EKErryk S. Katayama
Erryk S. Katayama
KJKaren Ji
Karen Ji
JWJordan M. Winter
Jordan M. Winter
Metabolites of tryptophan degradation are known to alter mood. Their effects have only been superficially examined in the context of pancreatic cancer. Herein, we study the role of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme important in the conversion of tryptophan to kynurenine, in a murine model of pancreatic cancer–associated depression. Behavioral tests (open field, forced swim, tail suspension, and elevated plus maze) and biochemical assays (LC-MS metabolomics) were used to characterize a depressive-phenotype in tumor-bearing mice (relative to non–tumor-bearing mice). In addition, we determine whether pharmacologic blockade of IDO1 affects mood in tumor-bearing mice. Immunocompetent mice bearing orthotopic pancreatic tumors exhibit depressive-like behavior relative to non–tumor-bearing mice. Pancreatic tumors strongly express IDO1. Consequently, serum kynurenine levels in tumor-bearing mice are elevated relative to non–tumor-bearing mice. Tumor-bearing mice treated with epacadostat, an IDO1 inhibitor, exhibited improved mood relative to mice receiving vehicle. There was a 95% reduction in serum kynurenine levels in mice receiving epacadostat relative to mice treated with vehicle. As confirmatory evidence of on-target activity, tumors of mice treated with epacadostat exhibited a compensatory increase in IDO1 protein levels. Escitalopram, an approved antidepressant, was ineffective at improving mood in tumor-bearing mice as measured by behavioral assays and did not affect kynurenine levels. Neither epacadostat, nor escitalopram, affected overall survival relative to vehicle. Mice with pancreatic cancer exhibit depressive-like behavior. Epacadostat was effective as an antidepressant for pancreatic cancer–associated depression in mice. These data offer a rationale to consider IDO1 inhibition as a therapeutic strategy to mitigate depressive symptoms in patients with pancreatic cancer.

1 June 2026 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
JHJonathan J. Hue
Jonathan J. Hue
MZMehrdad Zarei
Mehrdad Zarei
PSPriyashree Sunita
Priyashree Sunita
SASami O. Abul-Khoudoud
Sami O. Abul-Khoudoud
GDGoutam Dey
Goutam Dey
JWJordan M. Winter
Jordan M. Winter
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an immunosuppressive tumor microenvironment (TME) that limits the efficacy of immunotherapies. Many tumor-suppressive immune cells, including inflammatory macrophage subsets, rely on glycolysis to sustain effector function; however, the pancreatic TME is relatively glucose-limited. In this study, we investigated whether increasing glucose availability in the periphery, which in turn translates to increased intratumoral glucose, could enhance immune-based therapies in PDAC. In vitro, glucose restriction induced metabolic reprogramming of inflammatory (M1-like) macrophages toward an oxidative, M2-like state with reduced inflammatory effector markers. In immunocompetent mice, administration of 30% dextrose drinking water increased both peripheral and intratumoral glucose levels and modestly shifted tumor transcriptional profiles toward a more inflammatory state without altering overall immune cell abundance. When macrophage-targeting immunotherapies (colony stimulating factor 1 receptor inhibition with PLX3397 or C–C chemokine receptor type 2 inhibition with PF-4136309) were combined with systemic hyperglycemia, tumors exhibited a pronounced increase in iNOS+ M1-like macrophages, a reduction in arginase+ M2-like macrophages, enhanced CD8+ T-cell infiltration, and decreased abundance of tumor-associated fibroblasts. These immunotherapies improved overall survival in immunocompetent mice bearing orthotopic pancreatic tumors only when combined with hyperglycemia. Analyses of patient samples confirmed the presence of a favorable antitumor immune infiltrate with elevated glucose levels. Together, these findings identify glucose availability as a key regulator of macrophage polarization and immunotherapy efficacy in PDAC. Significance: PDAC is largely resistant to immunotherapies. Our findings identify glucose availability in the TME as a modifiable determinant of macrophage polarization and immunotherapy response. In preclinical models, transient hyperglycemia was associated with enhanced efficacy of macrophage-targeting immunotherapies and promoted a more inflammatory TME.

16 September 2024
Verified
Other
Open access
MZMehrdad Zarei
Mehrdad Zarei
OHOmid Hajihassani
Omid Hajihassani
JHJonathan J. Hue
Jonathan J. Hue
ALAlexander W. Loftus
Alexander W. Loftus
HGHallie J. Graor
Hallie J. Graor
JWJordan M. Winter
Jordan M. Winter
Pancreatic ductal adenocarcinoma (PDAC) is associated with a 5-year overall survival rate of just 13%, and development of chemotherapy resistance is nearly universal. PDAC cells overexpress wild-type isocitrate dehydrogenase 1 (IDH1) that can enable them to overcome metabolic stress, suggesting it could represent a therapeutic target in PDAC. Here, we found that anti-IDH1 therapy enhanced the efficacy of conventional chemotherapeutics. Chemotherapy treatment induced reactive oxygen species (ROS) and increased tricarboxylic acid cycle activity in PDAC cells, along with the induction of wild-type IDH1 expression as a key resistance factor. IDH1 facilitated PDAC survival following chemotherapy treatment by supporting mitochondrial function and antioxidant defense to neutralize ROS through the generation of α-ketoglutarate and NADPH, respectively. Pharmacologic inhibition of wild-type IDH1 with ivosidenib synergized with conventional chemotherapeutics in vitro and potentiated the efficacy of subtherapeutic doses of these drugs in vivo in murine PDAC models. This promising treatment approach is translatable through available and safe oral inhibitors and provides the basis of an open and accruing clinical trial testing this combination (NCT05209074).Significance: Targeting IDH1 improves sensitivity to chemotherapy by suppressing mitochondrial function and inducing oxidative stress, supporting the potential of the combination as an effective strategy for treating pancreatic cancer.